Composite endpoints increase event rates and statistical power but require careful component selection, individually adjudicated definitions, and reporting of component breakdowns to avoid overstating treatment effect. Common device examples include major adverse cardiac events (MACE) and target lesion failure. Components should be of similar clinical importance and likely to move in the same direction with treatment. Regulators expect each component to be reported separately so readers can see whether a less serious event is driving the overall result.

Why it matters

Standard practice in cardiovascular device trials (MACE, MALE, NACE); FDA reviewers focus on whether benefit is consistent across components.

Common pitfalls

•A common pitfall is including components with widely disparate clinical importance, which can obscure a treatment's true effect on patients. Another mistake is failing to pre-specify the hierarchy of components or how missing data for individual components will be handled. Over-interpreting a positive composite endpoint result without examining the contributions of each component can lead to misleading conclusions and regulatory scrutiny.
•Failing to define each component precisely and adjudicate them consistently across all study sites can introduce bias.
•Selecting components that are not causally linked to the disease or treatment mechanism can weaken the validity of the composite endpoint.
•Not adequately powering the study to detect a meaningful difference in the primary, most clinically relevant component, even if the composite endpoint shows significance, is a frequent error.

Sources

FDA Composite Endpoints Guidance · FDA
FDA - Clinical Trials and Human Subject Protection · FDA
ClinicalTrials.gov · NIH

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.